

Mark R Gilbert

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8405347/mark-r-gilbert-publications-by-citations.pdf>

Version: 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

424
papers

27,206
citations

78
h-index

153
g-index

446
ext. papers

32,702
ext. citations

4.8
avg, IF

6.96
L-index

#	Paper	IF	Citations
4 ²⁴	Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1963-72	2.2	2543
4 ²³	A randomized trial of bevacizumab for newly diagnosed glioblastoma. <i>New England Journal of Medicine</i> , 2014 , 370, 699-708	59.2	1775
4 ²²	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015 , 27, 728-43	24.3	672
4 ²¹	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4189-99	2.2	625
4 ²⁰	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4085-91	2.2	623
4 ¹⁹	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. <i>New England Journal of Medicine</i> , 2016 , 374, 1344-55	59.2	596
4 ¹⁸	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4722-9	2.2	593
4 ¹⁷	Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 79, 1487-94	2.2	487
4 ¹⁶	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , 2015 , 16, e534-e542	21.7	425
4 ¹⁵	Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. <i>Clinical Cancer Research</i> , 2005 , 11, 1462-6	12.9	386
4 ¹⁴	Chemoradiotherapy in malignant glioma: standard of care and future directions. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4127-36	2.2	385
4 ¹³	Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. <i>Clinical Cancer Research</i> , 2006 , 12, 4899-907	12.9	361
4 ¹²	Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2008 , 10, 162-70	1	315
4 ¹¹	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014 , 16, 81-91	1	290
4 ¹⁰	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 509-520	19.4	284
4 ⁰⁹	A multigene predictor of outcome in glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 49-57	1	274
4 ⁰⁸	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 116-21	1	241

407	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 324-33	2.1	241
406	Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3065-70	2.2	241
405	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. <i>Cancer Discovery</i> , 2012 , 2, 458-71	24.4	240
404	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015 , 17, 1188-98	1	224
403	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. <i>Clinical Cancer Research</i> , 2005 , 11, 7841-50	12.9	224
402	Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. <i>Journal of Neurosurgery</i> , 2008 , 109, 835-41	3.2	220
401	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015 , 129, 585-96	14.3	211
400	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. <i>Neuro-Oncology</i> , 2010 , 12, 95-103	1	201
399	Cerebral radiation necrosis. <i>Neurologist</i> , 2003 , 9, 180-8	1.6	187
398	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020 , 22, 1073-1113	1	178
397	Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2689-95	2.2	172
396	Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. <i>Clinical Cancer Research</i> , 2006 , 12, 4738-46	12.9	170
395	YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. <i>Clinical Cancer Research</i> , 2005 , 11, 3326-34	12.9	168
394	Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy 2018 , 6, 51		161
393	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019 , 576, 112-120	50.4	151
392	Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. <i>Cancer Immunology Research</i> , 2013 , 1, 112-22	12.5	146
391	Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3651-6	2.2	132
390	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012 , 123, 727-38	14.3	131

389	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. <i>Neuro-Oncology</i> , 2016 , 18, 639-48	1	124
388	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2010 , 96, 211-7	4.8	121
387	Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1485-91	2.2	118
386	Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. <i>Cancer Research</i> , 2017 , 77, 1709-1718	10.1	117
385	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2468-77	2.2	113
384	Association and interactions between DNA repair gene polymorphisms and adult glioma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 204-14	4	111
383	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014 , 16, 567-78	1	110
382	Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. <i>Neuro-Oncology</i> , 2017 , 19, 887-896	1	109
381	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 731-9 ²	2	108
380	Ependymomas in adults. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 240-7	6.6	106
379	IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. <i>British Journal of Cancer</i> , 2020 , 122, 1580-1589	8.7	105
378	Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 277-84	4	102
377	Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 147-53	4.8	100
376	Biology and management of ependymomas. <i>Neuro-Oncology</i> , 2016 , 18, 902-13	1	99
375	Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4076-84	2.2	98
374	The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. <i>Cancer</i> , 2005 , 104, 1468-77	6.4	96
373	Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. <i>Clinical Cancer Research</i> , 2003 , 9, 2940-9	12.9	92
372	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011 , 13, 353-61	1	90

371	Chemotherapy-induced peripheral neuropathy. <i>Oncology Nursing Forum</i> , 2005 , 32, 305-11	1.7	90
370	An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. <i>Journal of Neuro-Oncology</i> , 2002 , 57, 231-9	4.8	90
369	Central nervous system cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 352-400	7.3	89
368	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. <i>Neuro-Oncology</i> , 2010 , 12, 1061-70	1	88
367	A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. <i>Neuro-Oncology</i> , 2008 , 10, 208-15	1	88
366	Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2467-74	2.2	87
365	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. <i>Neuro-Oncology</i> , 2004 , 6, 21-7	1	86
364	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. <i>Neuro-Oncology</i> , 2015 , 17, 1148-56	1	84
363	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015 , 17, 992-8	1	83
362	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015 , 17, 440-7	1	83
361	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017 , 19, 1119-1126	1	82
360	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. <i>Neuro-Oncology</i> , 2011 , 13, 509-16	1	82
359	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012 , 14, 1511-8	1	82
358	Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. <i>Oncotarget</i> , 2014 , 5, 2208-20	3.3	82
357	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2011 , 13, 1118-24	1	81
356	A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. <i>Neuro-Oncology</i> , 2002 , 4, 261-7	1	81
355	Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. <i>Journal of Clinical Oncology</i> , 2014 , 32, 535-41	2.2	79
354	Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. <i>Neuro-Oncology</i> , 2010 , 12, 862-70	1	79

353	CBIO-01. TRANSCRIPTIONAL MODULATION OF BRACHYURY IN CHORDOMA. <i>Neuro-Oncology</i> , 2017 , 19, vi32-vi33	1	78
352	CSIG-34. PDGFR β SIGNALING MAINTAINS GLIOBLASTOMA SURVIVAL VIA HYPOXIA-INDUCED MITOPHAGY. <i>Neuro-Oncology</i> , 2017 , 19, vi57-vi57	1	78
351	IMMU-53. CO-ADMINISTRATION OF DEXAMETHASONE WITH CHECKPOINT BLOCKADE THERAPY INCREASES SURVIVAL IN BRAIN TUMOR MODEL. <i>Neuro-Oncology</i> , 2017 , 19, vi124-vi124	1	78
350	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2239-245	3.2	78
349	Neurologic complications of cancer and its treatment. <i>Current Oncology Reports</i> , 2010 , 12, 50-9	6.3	78
348	QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS). <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi217	1	78
347	TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021 , 3, i20-i20	0.9	78
346	EXTH-44. INHIBITION OF MeTK ACTIVATES GLIOBLASTOMA-ASSOCIATED MACROPHAGES AND INDUCES TUMOR CELL DEATH IN GLIOMA MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2019 , 21, vi91-vi91	1	78
345	QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , 2019 , 21, vi203-vi204	1	78
344	CBMT-07. BIOMARKERS OF AGGRESSIVENESS IN IDH MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi34-vi34	1	78
343	HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, vi111-vi112 ¹	1	78
342	HOUT-22. EVALUATING CLINICAL IMPACT UTILIZING THE RANO-PRO COLLABORATIVE'S STANDARDIZED PRIORITY CONSTRUCTS. <i>Neuro-Oncology</i> , 2019 , 21, vi116-vi117	1	78
341	EXTH-58. INHIBITION OF DNA TOPOISOMERASE 1 AND POLY(ADP-RIBOSE) POLYMERASE SYNERGISTICALLY INDUCES CELL DEATH IN GLIOBLASTOMA WITH PTEN LOSS. <i>Neuro-Oncology</i> , 2019 , 21, vi94-vi95	1	78
340	NIMG-32. CHALLENGES OF IMAGING INTERPRETATION TO PREDICT OLIGODENDROGLIOMA GRADE. <i>Neuro-Oncology</i> , 2019 , 21, vi168-vi168	1	78
339	RDNA-18. TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/p25: A NOVEL THERAPEUTIC APPROACH AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi225-vi225	1	78
338	QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENTS EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi218	1	78
337	RARE-21. A DESCRIPTIVE REPORT OF PATIENTS WITH RARE CENTRAL NERVOUS SYSTEM (CNS) CANCERS ON AN NCI-CONNECT CANCER MOONSHOT IMMUNE CHECKPOINT INHIBITOR TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi240-vi240	1	78
336	INNV-43. NUCLEIC ACID ADEQUACY FROM ARCHIVED FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE FOR NEXT-GENERATION SEQUENCING (NGS) IN NATIONAL CANCER INSTITUTE (NCI)- NATURAL HISTORY STUDY (NHS) OF PRIMARY CNS TUMOR. <i>Neuro-Oncology</i> , 2018 , 20, vi116-vi116	1	78

335	TMIC-32. INHIBITION OF MerTK MODULATES GLIOMA-ASSOCIATED MACROPHAGES AND MICROGLIA IN TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2018 , 20, vi263-vi263	1	78
334	HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi115-vi115	1	78
333	COMP-08. SURVIVING BY EXPLORING: COULD GLIOBLASTOMA CELLS FOLLOW THE THEORY OF EXPLORATORY ADAPTATION?. <i>Neuro-Oncology</i> , 2018 , 20, vi65-vi65	1	78
332	ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2018 , 20, vi7-vi7	1	78
331	CBMT-44. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839. <i>Neuro-Oncology</i> , 2018 , 20, vi42-vi42	1	78
330	INNV-38. THE NEURO-ONCOLOGY BRANCH TRANSLATIONAL RESEARCH IMMERSION PROGRAM: RESULTS FROM TWO YEARS OF DEVELOPMENT AND PARTICIPANT FEEDBACK. <i>Neuro-Oncology</i> , 2018 , 20, vi145-vi146	1	78
329	QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi215-vi215	1	78
328	DRES-18. SUMO1 AND VALOSIN-CONTAINING PROTEIN REGULATE RETINOID RECEPTOR PROTEIN TURNOVER A PROCESS DISRUPTED IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi79-vi79	1	78
327	EXTH-63. EFFICIENT ADCC-MEDIATED KILLING OF MALIGNANT MENINGIOMA CELLS USING AVELUMAB AND AN ENGINEERED HIGH AVIDITY NATURAL KILLER CELL LINE, haNK. <i>Neuro-Oncology</i> , 2018 , 20, vi98-vi98	1	78
326	EXTH-61. PARTNERSHIP FOR DEFINING THE IMPACT OF 12 SELECT RARE CNS TUMORS: A REPORT FROM CBTRUS AND THE NCI-CONNECT. <i>Neuro-Oncology</i> , 2018 , 20, vi98-vi98	1	78
325	CBMT-43. SINGLE LIVE TUMOR CELL METABOLISM VIA RAMAN IMAGING MICROSCOPY. <i>Neuro-Oncology</i> , 2018 , 20, vi42-vi42	1	78
324	EXTH-80. IMPAIRED PARP1 DNA REPAIR DEFINES CHEMO-SENSITIVITY IN IDH1-MUTATED CELL. <i>Neuro-Oncology</i> , 2018 , 20, vi102-vi102	1	78
323	HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT. <i>Neuro-Oncology</i> , 2018 , 20, vi113-vi113	1	78
322	IMMU-68. SINGLE-CELL PROTEOMIC ANALYSIS OF IMMUNE CELL RESPONSE TO CHECKPOINT BLOCKADE USING 30-PARAMETER FLOW CYTOMETRY. <i>Neuro-Oncology</i> , 2018 , 20, vi137-vi137	1	78
321	QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi216-vi216	1	78
320	RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM. <i>Neuro-Oncology</i> , 2018 , 20, vi241-vi241	1	78
319	INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCHS (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi145-vi145	1	78
318	CBMT-42. LOSS OF PROMOTER METHYLATION IN GLYCOLYTIC GENES IS ASSOCIATED WITH AGGRESSIVENESS IN IDH1-MUTANT LOWER GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, vi41-vi42	1	78

317	QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS).. <i>Neuro-Oncology, 2018, 20, vi220-vi220</i>	1	78
316	IMMU-38. TARGETING HYPOXIA DOWNSTREAM SIGNALING PROTEIN, CAIX FOR CAR-T CELL THERAPY AGAINST GLIOBLASTOMA (GBM). <i>Neuro-Oncology, 2018, 20, vi129-vi129</i>	1	78
315	TMIC-49. ACTIVATION OF THE Wnt/βCATENIN SIGNALING PATHWAY IN GLIOMA STEM CELLS IMPACTS ENDOTHELIAL CELL-CELL INTERACTION. <i>Neuro-Oncology, 2018, 20, vi267-vi267</i>	1	78
314	EXTH-58. ONC206, AN IMIPRIDONE FAMILY MEMBER, SUPPRESSES GLIOBLASTOMA CELLS VIA BLOCKING CANCER STEMNESS PATHWAYS. <i>Neuro-Oncology, 2018, 20, vi97-vi97</i>	1	78
313	DDIS-27. COMBINED INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND POLY (ADP-RIBOSE) POLYMERASE (PARP) IMPAIRS GLIOBLASTOMA CELL GROWTH. <i>Neuro-Oncology, 2018, 20, vi74-vi75</i>	1	78
312	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology, 2017, 35, 361-369</i>	2.2	76
311	Diffusely infiltrative low-grade gliomas in adults. <i>Journal of Clinical Oncology, 2006, 24, 1236-45</i>	2.2	76
310	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1191-202</i>	7.3	74
309	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology, 2017, 19, 669-677</i>	1	74
308	Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. <i>International Journal of Radiation Oncology Biology Physics, 2009, 73, 699-708</i>	4	73
307	Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. <i>Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1277-81</i>	4	71
306	Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. <i>Journal of Clinical Oncology, 2004, 22, 4282-9</i>	2.2	70
305	Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. <i>Neuro-Oncology, 2005, 7, 177-82</i>	1	70
304	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology, 2008, 21, 754-61</i>	7.1	68
303	The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. <i>Neuro-Oncology, 2016, 18, 252-60</i>	1	67
302	Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. <i>Journal of Neuro-Oncology, 2009, 94, 229-34</i>	4.8	67
301	Antiepileptic drugs for preventing seizures in people with brain tumors. <i>The Cochrane Library, 2008, CD004424</i>	9.4	67
300	Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. <i>Journal of Clinical Oncology, 1999, 17, 984-90</i>	2.2	67

299	Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. <i>Neuro-Oncology</i> , 2016 , 18, 779-89	1	66
298	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2014 , 32, 129-60	2.2	65
297	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 741-750	2.2	64
296	Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1627-32	2.2	61
295	Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. <i>Neuro-Oncology</i> , 2016 , 18, 1209-18	1	61
294	Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1517-23	7.3	60
293	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1809-1816	12.0	59
292	Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. <i>Oncotarget</i> , 2015 , 6, 11882-93	3.3	58
291	Bevacizumab for newly diagnosed glioblastoma. <i>New England Journal of Medicine</i> , 2014 , 370, 2048-9	59.2	58
290	Pregnancy and glial brain tumors. <i>Neuro-Oncology</i> , 2014 , 16, 1289-94	1	56
289	Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. <i>Neuro-Oncology</i> , 2009 , 11, 825-32	1	55
288	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. <i>JAMA Oncology</i> , 2017 , 3, 784-792	13.4	54
287	Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 58-61	1.9	54
286	Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. <i>Neuroepidemiology</i> , 2012 , 39, 116-24	5.4	54
285	A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007 , 81, 271-7	4.8	54
284	Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. <i>Neuro-Oncology</i> , 2013 , 15, 945-54	1	53
283	Practical strategies for management of fatigue and sleep disorders in people with brain tumors. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv65-72	1	53
282	Risk factors for fatigue severity in primary brain tumor patients. <i>Cancer</i> , 2010 , 116, 2707-15	6.4	53

281	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018 , 136, 227-237	14.3	52
280	Targeting WNT Signaling for Multifaceted Glioblastoma Therapy. <i>Frontiers in Cellular Neuroscience</i> , 2017 , 11, 318	6.1	52
279	Incidence and nature of neurologic problems in patients with solid tumors. <i>American Journal of Medicine</i> , 1986 , 81, 951-4	2.4	52
278	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. <i>Brain Pathology</i> , 2020 , 30, 863-866	6	51
277	Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. <i>Clinical Cancer Research</i> , 2011 , 17, 4872-81	12.9	50
276	Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. <i>Clinical Cancer Research</i> , 2012 , 18, 6032-9	12.9	50
275	Advances in molecular therapies in patients with brain tumors. <i>Cancer Control</i> , 2003 , 10, 125-37	2.2	50
274	Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor. <i>Acta Neuropathologica</i> , 2012 , 123, 285-7	14.3	49
273	Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 227-33	3.5	48
272	The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 299-306	4.2	46
271	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2008 , 10, 216-22	1	46
270	Anaplastic astrocytoma: diagnosis, prognosis, and management. <i>Seminars in Oncology</i> , 2004 , 31, 618-34	5.5	46
269	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 266-73	1	45
268	Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. <i>Brain Pathology</i> , 2013 , 23, 584-94	6	45
267	Central nervous system cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1114-51	7.3	45
266	Management of treatment-associated toxicities of anti-angiogenic therapy in patients with brain tumors. <i>Neuro-Oncology</i> , 2012 , 14, 1203-14	1	45
265	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. <i>International Journal of Oncology</i> , 2015 , 46, 1883-92	4.4	44
264	Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. <i>Journal of Neuro-Oncology</i> , 2006 , 80, 83-90	4.8	44

263	Venous thromboembolism (VTE) and glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 87-94	4.8	43
262	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 401-10	4.8	43
261	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , 2012 , 13, e196-204	21.7	43
260	Immunotherapy in CNS cancers: the role of immune cell trafficking. <i>Neuro-Oncology</i> , 2019 , 21, 37-46	1	42
259	Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. <i>Neuro-Oncology</i> , 2013 , 15, 936-44	1	42
258	Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. <i>Clinical Cancer Research</i> , 2008 , 14, 6640-6	12.9	42
257	An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). <i>Journal of Neuro-Oncology</i> , 2015 , 123, 85-91	4.8	41
256	A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 309-16	4.8	41
255	Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. <i>Journal of Neurosurgery</i> , 1995 , 82, 1053-8	3.2	40
254	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1-1	2.2	40
253	Treating recurrent glioblastoma: an update. <i>CNS Oncology</i> , 2015 , 4, 91-104	4	39
252	A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 487-494	4.8	39
251	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3407-3417	2.2	39
250	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020 , 22, 1262-1275	1	38
249	Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. <i>Seminars in Oncology</i> , 2011 , 38 Suppl 4, S21-33	5.5	38
248	Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. <i>Neuro-Oncology</i> , 2002 , 4, 268-77	1	38
247	MerTK as a therapeutic target in glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 92-102	1	37
246	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. <i>Neuro-Oncology</i> , 2010 , 12, 87-94	1	37

245	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. <i>Nature Communications</i> , 2018 , 9, 2126	17.4	37
244	Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. <i>Cancer Research</i> , 2019 , 79, 5218-5232	10.1	36
243	The effect of an adenosine A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. <i>Fluids and Barriers of the CNS</i> , 2018 , 15, 2	7	36
242	Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. <i>Journal of Clinical Oncology</i> , 2013 , 31, 131-61	2.2	35
241	Sleep-wake disturbance in patients with brain tumors. <i>Neuro-Oncology</i> , 2017 , 19, 323-335	1	34
240	Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. <i>Journal of Neuro-Oncology</i> , 2013 , 112, 83-9	4.8	34
239	Complementary and alternative medicine use and quality of life in patients with primary brain tumors. <i>Journal of Pain and Symptom Management</i> , 2006 , 32, 148-54	4.8	34
238	Pectoralis major myofascial onlay and myocutaneous flaps and pharyngocutaneous fistula in salvage laryngectomy. <i>Laryngoscope</i> , 2014 , 124, 2680-6	3.6	33
237	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 193-199	4.8	33
236	Clinical utility of the MDASI-BT in patients with brain metastases. <i>Journal of Pain and Symptom Management</i> , 2009 , 37, 331-40	4.8	33
235	Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. <i>Neuro-Oncology</i> , 2004 , 6, 15-20	1	33
234	Personal health records as portal to the electronic medical record. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 1-6	4.8	32
233	Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 597-605	4.8	32
232	Molecularly targeted therapies for malignant gliomas: advances and challenges. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 641-61	3.5	32
231	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. <i>Neuro-Oncology</i> , 2017 , 19, 252-258	1	32
230	Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. <i>BMC Cancer</i> , 2018 , 18, 239	4.8	31
229	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015 , 13, 293	11.4	31
228	Central nervous system cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 456-504	7.3	31

227	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 38-44	4	30
226	Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. <i>Neuro-Oncology</i> , 2019 , 21, 1436-1446	1	30
225	Targeted therapy in gliomas. <i>Current Oncology Reports</i> , 2014 , 16, 379	6.3	30
224	New molecular targets in malignant gliomas. <i>Current Opinion in Neurology</i> , 2007 , 20, 712-8	7.1	30
223	Advances in treating glioblastoma. <i>F1000prime Reports</i> , 2014 , 6, 46		30
222	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). <i>Journal of Neuro-Oncology</i> , 2016 , 130, 31-42	4.8	29
221	Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. <i>Journal of Neurosurgery: Spine</i> , 2010 , 12, 421-30	2.8	29
220	Novel Targeting of Transcription and Metabolism in Glioblastoma. <i>Clinical Cancer Research</i> , 2018 , 24, 1124-1137	12.9	28
219	Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. <i>Neuro-Oncology</i> , 2014 , 16, 303-9	1	28
218	The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. <i>Cancer</i> , 2011 , 117, 3222-8	6.4	28
217	Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. <i>Cancer</i> , 2011 , 117, 5133-41	6.4	28
216	Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Cancer</i> , 2019 , 125, 424-433	6.4	28
215	Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. <i>Cancer</i> , 2010 , 116, 2242-9	6.4	27
214	Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2000-2000	2.2	27
213	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. <i>Clinical Cancer Research</i> , 2019 , 25, 2305-2313	12.9	27
212	Current challenges in designing GBM trials for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015 , 123, 331-7	4.8	26
211	Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014 , 119, 135-40	4.8	26
210	Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. <i>Neuro-Oncology</i> , 2010 , 12, 444-52	1	26

209	Predictors of survival among older adults with ependymoma. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 183-9	4.8	25
208	Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. <i>Cancer</i> , 2013 , 119, 2747-53	6.4	25
207	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 405-412	4.8	24
206	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3340-6	12.9	23
205	Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 305-11	4.8	23
204	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. <i>Neuro-Oncology</i> , 2018 , 20, 966-974	1	22
203	Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011 , 102, 273-80	4.8	22
202	Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease. <i>Neuro-Oncology</i> , 2017 , 19, 1173-1182	1	21
201	Uncertainty, mood states, and symptom distress in patients with primary brain tumors: analysis of a conceptual model using structural equation modeling. <i>Cancer</i> , 2013 , 119, 2796-806	6.4	21
200	A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 1167-72	1	21
199	Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2008 , 10, 631-42	1	21
198	Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1 β human glioma stem cells. <i>Oncotarget</i> , 2017 , 8, 40233-40245	3.3	21
197	It is time to include patients with brain tumors in phase I trials in oncology. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3211-3	2.2	20
196	Response of glioblastomas to EGFR kinase inhibitors. <i>New England Journal of Medicine</i> , 2006 , 354, 525-6; author reply 525-6	59.2	20
195	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology</i> , 2020 , 21, e97-e103	21.7	19
194	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. <i>Neuro-Oncology</i> , 2018 , 20, 1400-1410	1	19
193	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018 , 136, 79-86	4.8	19
192	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012 , 118, 5026-37	6.4	19

191	ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response. <i>Cancer Investigation</i> , 2004 , 22, 257-61	2.1	19
190	Treatment of astrocytomas. <i>Current Opinion in Neurology</i> , 2005 , 18, 632-8	7.1	19
189	Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 145-152	4.8	19
188	IDH1 mutations induce organelle defects via dysregulated phospholipids. <i>Nature Communications</i> , 2021 , 12, 614	17.4	19
187	Toward Personalized Targeted Therapeutics: An Overview. <i>Neurotherapeutics</i> , 2017 , 14, 256-264	6.4	18
186	The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 585-607	4.8	18
185	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2016 , 18 Suppl 2, ii26-ii36	1	18
184	Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 519-28	5.4	18
183	Use of complementary and alternative medical therapy by patients with primary brain tumors. <i>Current Neurology and Neuroscience Reports</i> , 2008 , 8, 264-8	6.6	18
182	High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 101	7.3	17
181	Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. <i>Cancers</i> , 2020 , 12,	6.6	17
180	Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). <i>Journal of Neuro-Oncology</i> , 2012 , 110, 293-300	4.8	17
179	Utility of positron-emission tomography/computed tomography imaging in the management of the neck in recurrent laryngeal cancer. <i>Laryngoscope</i> , 2012 , 122, 821-5	3.6	17
178	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. <i>JCI Insight</i> , 2019 , 4,	9.9	17
177	C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. <i>Brain Tumor Pathology</i> , 2015 , 32, 105-11	3.2	16
176	The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. <i>Neuro-Oncology</i> , 2015 , 17, 1114-20	1	16
175	A case of soft tissue metastasis from glioblastoma and review of the literature. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 167-72	4.8	16
174	Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. <i>Neuro-Oncology</i> , 2020 , 22, 480-492	1	16

173	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015 , 17 Suppl 7, vii32-vii40	1	15
172	T lymphocyte-targeted immune checkpoint modulation in glioma 2020 , 8,		15
171	Hope and mood changes throughout the primary brain tumor illness trajectory. <i>Neuro-Oncology</i> , 2016 , 18, 119-25	1	15
170	Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 407-11	4.8	15
169	New treatments for malignant gliomas: careful evaluation and cautious optimism required. <i>Annals of Internal Medicine</i> , 2006 , 144, 371-3	8	15
168	The Treatment of Malignant Gliomas. <i>Current Treatment Options in Neurology</i> , 2005 , 7, 293-303	4.4	15
167	Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 415-427	4.8	15
166	LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. <i>Cancer Letters</i> , 2018 , 415, 217-226	9.9	15
165	Wound healing complications in brain tumor patients on Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 501-6	4.8	14
164	Clinical presentation and outcomes for adult ependymoma patients. <i>Cancer</i> , 2017 , 123, 494-501	6.4	14
163	Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. <i>Neuro-Oncology</i> , 2015 , 17, 999-1006	1	14
162	Net clinical benefit: functional endpoints in brain tumor clinical trials. <i>Current Oncology Reports</i> , 2007 , 9, 60-5	6.3	14
161	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021 , 23, 1360-1370	1	14
160	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020 , 16, 899-909	3.6	13
159	The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking. <i>Oncotarget</i> , 2017 , 8, 33316-33328	3.3	13
158	Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. <i>Cancer</i> , 2012 , 118, 3599-606	6.4	13
157	Glioblastoma. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 485-506	3	13
156	Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. <i>Journal of Neuro-Oncology</i> , 2013 , 115, 513-20	4.8	13

155	CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 476-82 ⁴		13
154	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA2010-LBA2010	2.2	13
153	Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation. <i>Nature Communications</i> , 2019 , 10, 5704	17.4	13
152	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 181-188	4.8	12
151	A Transgenic Mouse Model of Pacak?Zhuang Syndrome with An Gain-of-Function Mutation. <i>Cancers</i> , 2019 , 11,	6.6	12
150	Management of patients with low-grade gliomas. <i>Neurologic Clinics</i> , 2007 , 25, 1073-88, ix	4.5	12
149	Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2012-2012	2.2	12
148	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020 , 22, 601-612	1	12
147	The functional interplay between systemic cancer and the hematopoietic stem cell niche. <i>Pharmacology & Therapeutics</i> , 2016 , 168, 53-60	13.9	12
146	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). <i>Neuro-Oncology</i> , 2019 , 21, vi17-vi17	1	12
145	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. <i>Neurosurgery</i> , 2019 , 84, 945-953	3.2	12
144	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021 , 23, 1337-1347	1	12
143	Ependymomas arising outside of the central nervous system: A case series and literature review. <i>Journal of Clinical Neuroscience</i> , 2018 , 47, 202-207	2.2	11
142	Toward Single-Organelle Lipidomics in Live Cells. <i>Analytical Chemistry</i> , 2019 , 91, 11380-11387	7.8	11
141	Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017 , 76, 697-708	3.1	11
140	Anaplastic oligodendroglial tumors: a tale of two trials. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2689-90	2.2	11
139	Efficacy of osimertinib against EGFRVIII+ glioblastoma. <i>Oncotarget</i> , 2020 , 11, 2074-2082	3.3	11
138	Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk. <i>Carcinogenesis</i> , 2010 , 31, 1762-9	4.6	10

137	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021 , 23, 468-477	1	10
136	Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 53-63	4.8	9
135	Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. <i>Neuro-Oncology</i> , 2018 , 20, 799-809	1	9
134	Primary brain tumors and posterior reversible encephalopathy syndrome. <i>Neuro-Oncology Practice</i> , 2014 , 1, 184-190	2.2	9
133	Impact of recall period on primary brain tumor patient's self-report of symptoms. <i>Neuro-Oncology Practice</i> , 2014 , 1, 55-63	2.2	9
132	Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/ β Catenin Signaling in IDH1-mutant Gliomas. <i>Translational Oncology</i> , 2020 , 13, 125-134	4.9	9
131	Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. <i>Radiology</i> , 2019 , 290, 467-476	20.5	9
130	Glucocorticoids and immune checkpoint inhibitors in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021 , 151, 13-20	4.8	9
129	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021 , 26, e847-e858	5.7	9
128	NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001. <i>Neuro-Oncology</i> , 2018 , 20, vi172-vi172	1	9
127	Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 341-8	4.8	8
126	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020 , 22, 1249-1261	1	8
125	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1505-1515	1	8
124	Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2019-2019	2.2	8
123	Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 1027-33	2.9	8
122	Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma. <i>Frontiers in Oncology</i> , 2021 , 11, 672508	5.3	8
121	Isolation and Propagation of Glioma Stem Cells from Acutely Resected Tumors. <i>Methods in Molecular Biology</i> , 2016 , 1516, 361-369	1.4	8
120	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa065	0.9	7

119	Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3 σ in oncocytomas. <i>Journal of Pathology</i> , 2018 , 245, 361-372	9.4	7
118	Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 665-72	7.3	7
117	Seizure risk in brain tumor patients with conversion to generic levetiracetam. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 137-41	4.8	7
116	Advances in the treatment of primary brain tumors: dawn of a new era?. <i>Current Oncology Reports</i> , 2006 , 8, 45-9	6.3	7
115	Application of advances in molecular biology to the treatment of brain tumors. <i>Current Oncology Reports</i> , 2000 , 2, 425-33	6.3	7
114	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019 , 84, 66-76	3.2	7
113	Creating clinical trial designs that incorporate clinical outcome assessments. <i>Neuro-Oncology</i> , 2016 , 18 Suppl 2, ii21-ii25	1	6
112	Textiloma resembling anaplastic progression of an isocitrate dehydrogenase 1 (IDH1) mutant, low grade glioma. <i>Journal of Neuro-Oncology</i> , 2013 , 111, 377-9	4.8	6
111	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. <i>Targeted Oncology</i> , 2013 , 8, 117-25	5	6
110	Personal health records, symptoms, uncertainty, and mood in brain tumor patients. <i>Neuro-Oncology Practice</i> , 2014 , 1, 64-70	2.2	6
109	A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. <i>Investigational New Drugs</i> , 2003 , 21, 429-33	4.3	6
108	Neoplastic meningitis: a unique disease process or a 'test tube' for evaluating cancer treatments?. <i>Current Oncology Reports</i> , 2003 , 5, 11-4	6.3	6
107	THE NEUROTOXICITY OF CANCER CHEMOTHERAPY. <i>Neurologist</i> , 1998 , 4, 43-53	1.6	6
106	Sphingolipid Pathway as a Source of Vulnerability in IDH1 Glioma. <i>Cancers</i> , 2020 , 12,	6.6	6
105	Metabolic plasticity of IDH1 glioma cell lines is responsible for low sensitivity to glutaminase inhibition. <i>Cancer & Metabolism</i> , 2020 , 8, 23	5.4	6
104	Magnetic resonance spectroscopy for the study of cns malignancies. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2021 , 122, 23-41	10.4	6
103	Case-based review: ependymomas in adults. <i>Neuro-Oncology Practice</i> , 2018 , 5, 142-153	2.2	6
102	Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy. <i>Biosensors</i> , 2018 , 9,	5.9	5

101	Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020 , 148, 231-244	4.8	5
100	Brain metastases: still an 'orphan' disease?. <i>Current Oncology Reports</i> , 2001 , 3, 463-6	6.3	5
99	Early diagnosis of spinal epidural metastases using out-patient computed tomographic myelography. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 495-9		5
98	Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2002-2002	2.2	5
97	Clinical correlates for immune checkpoint therapy: significance for CNS malignancies. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdaa161	0.9	5
96	Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials. <i>Neuro-Oncology Practice</i> , 2019 , 6, 81-92	2.2	5
95	Association of genetic variants with fatigue in patients with malignant glioma. <i>Neuro-Oncology Practice</i> , 2018 , 5, 122-128	2.2	5
94	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021 , 142, 827-839	14.3	5
93	Significant predictors of patients' uncertainty in primary brain tumors. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 507-15	4.8	4
92	Renewing interest in targeting angiogenesis in glioblastoma. <i>Lancet Oncology, The</i> , 2014 , 15, 907-8	21.7	4
91	Incidental thyroid cancer found during surgery for head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2012 , 147, 647-53	5.5	4
90	The treatment of neoplastic meningitis. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1929-35	4	4
89	A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2005-2005	2.2	4
88	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11527-11527	2.2	4
87	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. <i>JAMA Ophthalmology</i> , 2020 , 138, 148-155	3.9	4
86	TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. <i>Cancers</i> , 2020 , 12,	6.6	4
85	Synthetic lethality-mediated precision oncology via the tumor transcriptome. <i>Cell</i> , 2021 , 184, 2487-2502	16.3	4
84	Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. <i>Neuro-Oncology</i> , 2021 ,	1	4

83	Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma. <i>Cancers</i> , 2020 , 12,	6.6	3
82	The prevalence of altered body image in patients with primary brain tumors: an understudied population. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 397-404	4.8	3
81	Retinoid receptor turnover mediated by sumoylation, ubiquitination and the valosin-containing protein is disrupted in glioblastoma. <i>Scientific Reports</i> , 2019 , 9, 16250	4.9	3
80	The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. <i>Neuro-Oncology Practice</i> , 2019 , 6, 473-478	2.2	3
79	Improving patient outcomes in glioblastoma through integration of recent data: introduction. <i>Seminars in Oncology</i> , 2011 , 38 Suppl 4, S1	5.5	3
78	Chemotherapy of astrocytomas: an overview. <i>Seminars in Oncology Nursing</i> , 1998 , 14, 18-25	3.7	3
77	Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA). <i>Advanced Therapeutics</i> , 2020 , 3, 2000044	4.9	3
76	Developmental vascular malformations in EPAS1 gain-of-function syndrome. <i>JCI Insight</i> , 2021 , 6,	9.9	3
75	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3298-3306	12.9	3
74	Molecularly Targeted Clinical Trials. <i>Neurosurgery Clinics of North America</i> , 2021 , 32, 191-210	4	3
73	The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications. <i>Neuro-Oncology</i> , 2021 , 23, 1647-1655	1	3
72	Progress in rare central nervous system tumors. <i>Current Opinion in Neurology</i> , 2019 , 32, 895-906	7.1	3
71	Multidose Botulinum Toxin A for Intralaryngeal Injection: A Cost Analysis. <i>Journal of Voice</i> , 2019 , 33, 159-161	1.9	3
70	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021 , 23, 1125-1138 [†]		3
69	Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. <i>Neuro-Oncology Practice</i> , 2018 , 5, 56-63	2.2	3
68	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1634-5	2.2	2
67	Brain tumor clinical trials: pitfalls and promise for the future. <i>Current Oncology Reports</i> , 2000 , 2, 473-5	6.3	2
66	Sinking skin flap syndrome in glioblastoma. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	2

65	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Journal of Neuro-Oncology</i> , 2021 , 155, 363-372	4.8	2
64	IDH1 Mutations Induce Organelle Defects Via Dysregulated Phospholipids		2
63	Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 680-687	3.6	2
62	A Novel In Vitro Device to Deliver Induced Electromagnetic Fields to Cell and Tissue Cultures. <i>Biophysical Journal</i> , 2020 , 119, 2378-2390	2.9	2
61	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa007	0.9	2
60	RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS. <i>Neuro-Oncology</i> , 2019 , 21, vi207-vi207	1	2
59	Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers. <i>Neuro-Oncology</i> , 2021 , 23, S4-S15	1	2
58	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi164-vi164	1	2
57	RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. <i>Neuro-Oncology</i> , 2018 , 20, vi241-vi241	1	2
56	Differential expression of an endogenous retroviral element [HERV-K(HML-6)] is associated with reduced survival in glioblastoma patients.. <i>Scientific Reports</i> , 2022 , 12, 6902	4.9	2
55	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3107-8	2.2	1
54	On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success. <i>Current Oncology Reports</i> , 2013 , 15, 24-6	6.3	1
53	Alveolar ridge mucosa protection during suspension laryngoscopy in the edentulous patient. <i>Ear, Nose and Throat Journal</i> , 2011 , 90, E31-2	1	1
52	Novel clinical trials in neuro-oncology. <i>Clinical Investigation</i> , 2011 , 1, 781-794		1
51	Patient profiling for treatment toxicity: potential use of clinical and genomic factors. <i>Current Oncology Reports</i> , 2011 , 13, 37-41	6.3	1
50	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.. <i>Acta Neuropathologica</i> , 2022 , 143, 403	14.3	1
49	Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 58	2.6	1
48	Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2039-2039	2.2	1

47	Cysteine is a limiting factor for glioma proliferation and survival. <i>Molecular Oncology</i> , 2021 ,	7.9	1
46	Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1579-1584	7.3	1
45	Neurologic Complications 2008 , 945-967		1
44	Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review. <i>Neuro-Oncology Practice</i> , 2020 , 7, 477-489	2.2	1
43	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa124	0.9	1
42	Letter to the Editor Re: Mohile et al. <i>Neuro-Oncology</i> , 2020 , 22, 1048-1049	1	1
41	Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 161-170	4.8	1
40	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
39	Impact of age on the circadian visual system and the sleep-wake cycle in mus musculus. <i>Npj Aging and Mechanisms of Disease</i> , 2021 , 7, 10	5.5	1
38	BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. <i>Neuro-Oncology Practice</i> , 2021 , 8, 627-638	2.2	1
37	Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. <i>Cancers</i> , 2021 , 13,	6.6	1
36	Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies. <i>Frontiers in Oncology</i> , 2021 , 11, 719091	5.3	1
35	QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS. <i>Neuro-Oncology</i> , 2019 , 21, vi205-vi206	1	1
34	Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. <i>Neuro-Oncology</i> , 2021 , 23, S30-S38	1	1
33	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 601452	5.3	1
32	INNV-41. MY STORI -- A SYMPTOM TRACKING AND REPORTING INSTRUMENT MOBILE APPLICATION FOR CENTRAL NERVOUS SYSTEM CANCER PATIENTS. <i>Neuro-Oncology</i> , 2018 , 20, vi146-vi146		1
31	ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi13-vi13	1	1
30	PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP). <i>Neuro-Oncology</i> , 2018 , 20, vi170-vi170	1	1

29	Report of Canonical - Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
28	Effects of Cognitive Reserve on Cognition in Individuals With Central Nervous System Disease. <i>Cognitive and Behavioral Neurology</i> , 2021 , 34, 245-258	1.6	1
27	Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model. <i>Molecular Cancer Research</i> , 2021 , 19, 2081-2095	6.6	1
26	Applications in Malignant Brain Tumors 2006 , 165-186		1
25	Immunotherapeutic Approaches for Glioblastoma Treatment.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
24	Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin I.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 126	12.8	1
23	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021 , 13,	6.6	1
22	Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.. <i>CNS Oncology</i> , 2022 , CNS83	4	0
21	A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2061-2061	2.2	0
20	Neurologic Complications 2020 , 688-706.e7		0
19	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. <i>Neuro-Oncology Practice</i> , 2021 , 8, 460-474	2.2	0
18	Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab073	0.9	0
17	DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY. <i>Neuro-Oncology</i> , 2019 , 21, vi67-vi67	1	0
16	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021 , 8, 417-425	2.2	0
15	CBMT-46. MICROENVIRONMENT-DERIVED MITOCHONDRIA PRIME GLIOMA CHEMORESISTANCE BY AUGMENTING NAD+ METABOLISM AND PARP-DEPENDENT DNA REPAIR. <i>Neuro-Oncology</i> , 2018 , 20, vi42-vi42	1	0
14	Accrual and access to neuro-oncology trials in the United States.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vda048	0.48	0
13	Ependymomas 2017 , 907-916		
12	Investigating therapies in ependymoma. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 761-773	1.1	

- 11 Establishing the standard of care for patients with newly diagnosed and recurrent glioblastoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 112-7 7.1
- 10 Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?. *Nature Clinical Practice Neurology*, **2007**, 3, 14-5
- 9 Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. *Comprehensive Psychoneuroendocrinology*, **2021**, 8, 100099 1.1
- 8 Ependymomas **2011**, 249-262
- 7 Ependymomas86-94
- 6 Neurologic Complications **2014**, 822-844.e6
- 5 Another layer of immune complication in glioblastoma: inducible co-stimulator and its ligand. *Neuro-Oncology*, **2020**, 22, 305-306 1
- 4 QLIF-17. THE IMPORTANCE OF THE CERN FOUNDATION ADULT EPENDYMOMA OUTCOMES PROJECT. *Neuro-Oncology*, **2016**, 18, vi159-vi159 1
- 3 EXTH-24. TG02 SYNERGIZES WITH TEMOZOLOMIDE TO INHIBIT GLIOBLASTOMA GROWTH. *Neuro-Oncology*, **2016**, 18, vi64-vi64 1
- 2 Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.. *Journal of Pharmaceutical and Biomedical Analysis*, **2022**, 213, 114685 3.5
- 1 A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.. *Neuro-Oncology Advances*, **2022**, 4, vdab192 0.9